Chaggar Parminder S, Shaw Steven M, Williams Simon G
North West Heart Centre, University Hospital of South Manchester, Manchester, UK.
Cardiovasc Ther. 2015 Aug;33(4):236-41. doi: 10.1111/1755-5922.12130.
Digoxin is the oldest known treatment for heart failure (HF) and has been demonstrated to reduce admissions for worsening heart failure in a large randomized trial recruiting patients in sinus rhythm with heart failure and ejection fraction <45%. This study forms the basis for current international guidelines recommending that digoxin should be considered in patients with symptomatic HF despite optimal doses of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and mineralocorticoid receptor antagonists in addition to device therapy, if indicated. However, digoxin predates mortality reducing HF therapies, and this article reviews the historical and recent data.
Multiple PubMed searches were performed including, but not limited to, the search terms "digoxin," "heart failure," "efficacy," "treatment," "side-effects," "morbidity," "mortality," and "arrythmia." Articles were excluded if not relevant, not in English or without abstract. Reference lists of relevant articles were manually searched for further references. Due to the large number of articles retrieved, a selection was reviewed based on the authors' best judgement.
Three randomized controlled trials and three large contemporary observational reports of digoxin therapy in heart failure and sinus rhythm were retrieved. Other studies were noted that included patients with heart failure and atrial fibrillation, which were also reviewed.
Definitive randomized evidence of digoxin efficacy as add-on therapy in HF is lacking because most landmark trials of modern HF disease modifying agents postdate the randomized studies of digoxin. Furthermore, questions remain regarding the optimum dose of digoxin and there are signals that digoxin may be harmful in some patients with HF. All contemporary data for digoxin in HF are derived from observational studies and the findings are conflicting. Despite two centuries of experience using cardiac glycosides to treat HF, fundamental questions regarding the efficacy and safety of digoxin in HF remain unanswered.
地高辛是已知最古老的心力衰竭(HF)治疗药物,在一项大型随机试验中已证明,对于窦性心律且心力衰竭伴射血分数<45%的患者,地高辛可减少因心力衰竭恶化而入院的次数。该研究为当前国际指南提供了依据,指南建议,对于有症状的心力衰竭患者,尽管已使用了最佳剂量的血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、β受体阻滞剂和盐皮质激素受体拮抗剂,且在有指征时进行了器械治疗,但仍应考虑使用地高辛。然而,地高辛早于降低死亡率的心力衰竭治疗方法,本文回顾了历史和近期数据。
进行了多次PubMed检索,包括但不限于检索词“地高辛”“心力衰竭”“疗效”“治疗”“副作用”“发病率”“死亡率”和“心律失常”。如果文章不相关、非英文或无摘要,则将其排除。手动检索相关文章的参考文献列表以获取更多参考文献。由于检索到的文章数量众多,根据作者的最佳判断对部分文章进行了审阅。
检索到三项关于地高辛治疗心力衰竭和窦性心律的随机对照试验以及三项大型当代观察性报告。还提及了其他纳入心力衰竭和心房颤动患者的研究,并对其进行了回顾。
缺乏地高辛作为心力衰竭附加治疗疗效的确切随机证据,因为现代心力衰竭疾病修饰药物的大多数里程碑式试验都晚于地高辛的随机研究。此外,关于地高辛的最佳剂量仍存在疑问,有迹象表明地高辛可能对某些心力衰竭患者有害。目前所有关于地高辛治疗心力衰竭的当代数据均来自观察性研究,且研究结果相互矛盾。尽管使用强心苷治疗心力衰竭已有两个世纪的经验,但关于地高辛在心力衰竭中的疗效和安全性的基本问题仍未得到解答。